Insider Selling: Relay Therapeutics (NASDAQ:RLAY) CFO Sells 17,717 Shares of Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $12.86, for a total value of $227,840.62. Following the transaction, the chief financial officer directly owned 195,178 shares of the company’s stock, valued at $2,509,989.08. This trade represents a 8.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Thomas Catinazzo also recently made the following trade(s):

• On Tuesday, April 28th, Thomas Catinazzo sold 972 shares of Relay Therapeutics stock. The shares were sold at an average price of $14.79, for a total transaction of $14,375.88.
• On Tuesday, April 7th, Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock. The shares were sold at an average price of $13.01, for a total transaction of $230,498.17.
• On Thursday, April 9th, Thomas Catinazzo sold 1,800 shares of Relay Therapeutics stock. The stock was sold at an average price of $15.00, for a total transaction of $27,000.00.

Relay Therapeutics Price Performance

RLAY traded down $0.44 during midday trading on Thursday, reaching $12.78. 4,381,117 shares of the company’s stock were exchanged, compared to its average volume of 2,784,902. Relay Therapeutics, Inc. has a 1-year low of $2.67 and a 1-year high of $17.32. The stock has a market capitalization of $2.45 billion, a PE ratio of -8.14 and a beta of 1.74. The business’s 50-day moving average price is $12.37 and its 200 day moving average price is $9.48.

Relay Therapeutics (NASDAQ:RLAY) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). The firm had revenue of $3.00 million for the quarter, compared to analyst estimates of $5.58 million. As a group, analysts expect that Relay Therapeutics, Inc. will post -1.6 EPS for the current fiscal year.

Institutional Trading of Relay Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Sanctuary Advisors LLC boosted its stake in Relay Therapeutics by 1.1% in the 1st quarter. Sanctuary Advisors LLC now owns 143,816 shares of the company’s stock worth $1,431,000 after buying an additional 1,588 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Relay Therapeutics by 26.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,422 shares of the company’s stock worth $71,000 after acquiring an additional 1,757 shares during the period. Abel Hall LLC boosted its position in shares of Relay Therapeutics by 16.2% in the fourth quarter. Abel Hall LLC now owns 12,984 shares of the company’s stock worth $110,000 after acquiring an additional 1,809 shares during the last quarter. Cresset Asset Management LLC boosted its position in shares of Relay Therapeutics by 5.0% in the third quarter. Cresset Asset Management LLC now owns 38,932 shares of the company’s stock worth $203,000 after acquiring an additional 1,848 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC grew its holdings in Relay Therapeutics by 8.1% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 27,871 shares of the company’s stock valued at $145,000 after purchasing an additional 2,079 shares during the period. 96.98% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Barclays boosted their price target on Relay Therapeutics from $17.00 to $21.00 and gave the stock an “overweight” rating in a report on Wednesday, April 8th. Guggenheim lifted their price objective on Relay Therapeutics from $15.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. Wall Street Zen downgraded shares of Relay Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Wells Fargo & Company upped their price objective on shares of Relay Therapeutics from $17.00 to $21.00 and gave the company an “overweight” rating in a research note on Tuesday, April 28th. Finally, JonesTrading began coverage on shares of Relay Therapeutics in a research report on Tuesday, April 14th. They set a “hold” rating and a $18.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $20.56.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.